Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alliance for Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$14,083,925

20 payments

Through program year 2025, Alliance for Clinical Trials is reported as receiving $14,083,925 in research payments, across 20 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $12,064,065 6
2024 Research $1,407,159 6
2023 Research $431,991 4
2022 Research $19,800 1
2020 Research $53,637 1
2019 Research $107,274 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $12,521,562 14 payments
  2. AstraZeneca Pharmaceuticals LP $1,292,481 4 payments
  3. Array BioPharma Inc. $266,212 1 payment
  4. GlaxoSmithKline, LLC. $3,670 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib $11,327,552 2 payments
  2. A042001 A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphiachromosomenegative Acute Lymphoblastic Leukemia Wi261343 $927,654 7 payments
  3. CHIO3 Trial Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable stage IIIA Non Small Cell Lung Cancer $805,444 1 payment
  4. Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer $429,466 1 payment
  5. Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II and III Braf V600e Colon Cancerwi261502 $266,212 1 payment
  6. Wi208323 Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin A Conjugated Anticd22 Monoclonal Antibody to Frontline Therapy in Young Adults Ages 1639 Years With Newly Diagnosed Precursor Bcell All $159,082 3 payments
  7. Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin A Conjugated Anticd22 Monoclonal Antibody to Frontline Therapy in Young Adults Ages 1639 Years With Newly Diagnosed Precursor Bcell All $107,274 2 payments
  8. Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations $57,571 2 payments
  9. Phase II Trial of Smo/ Akt/ Nf2 Inhibitors in Progressive Meningiomas $3,670 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record